Upgrades STERIS (NYSE:STE) to “Buy”

STERIS (NYSE:STEGet Free Report) was upgraded by analysts at from a “hold” rating to a “buy” rating in a report released on Saturday.

A number of other equities research analysts have also recently commented on the company. Stephens reissued an “overweight” rating and issued a $250.00 target price on shares of STERIS in a research note on Friday, February 9th. KeyCorp started coverage on shares of STERIS in a research note on Tuesday, February 6th. They set an “overweight” rating and a $253.00 price objective for the company. Piper Sandler reiterated a “neutral” rating and issued a $225.00 target price (up previously from $220.00) on shares of STERIS in a research note on Friday. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Friday. Finally, TheStreet raised STERIS from a “c+” rating to a “b” rating in a research report on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, STERIS presently has an average rating of “Moderate Buy” and a consensus target price of $241.60.

Read Our Latest Analysis on STE

STERIS Price Performance

STE opened at $231.33 on Friday. The stock has a fifty day simple moving average of $216.99 and a two-hundred day simple moving average of $216.17. The company has a market cap of $22.86 billion, a price-to-earnings ratio of 60.56 and a beta of 0.81. The company has a current ratio of 3.06, a quick ratio of 1.49 and a debt-to-equity ratio of 0.49. STERIS has a 12-month low of $195.47 and a 12-month high of $254.00.

STERIS (NYSE:STEGet Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The medical equipment provider reported $2.58 EPS for the quarter, topping the consensus estimate of $2.41 by $0.17. STERIS had a net margin of 6.95% and a return on equity of 13.73%. The business had revenue of $1.42 billion for the quarter, compared to analyst estimates of $1.41 billion. During the same quarter in the previous year, the firm posted $2.30 earnings per share. STERIS’s quarterly revenue was up 10.8% on a year-over-year basis. Research analysts predict that STERIS will post 9.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On STERIS

A number of large investors have recently made changes to their positions in STE. Millburn Ridgefield Corp bought a new stake in STERIS during the third quarter valued at approximately $25,000. Catalyst Capital Advisors LLC purchased a new stake in shares of STERIS in the 3rd quarter worth $25,000. First Personal Financial Services purchased a new stake in STERIS in the 1st quarter worth approximately $25,000. J.Safra Asset Management Corp raised its stake in STERIS by 77.9% during the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 53 shares during the period. Finally, Quent Capital LLC lifted its holdings in STERIS by 112.7% during the first quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 71 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors.


(Get Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Featured Articles

Analyst Recommendations for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with's FREE daily email newsletter.